182 related articles for article (PubMed ID: 15310397)
1. Tamoxifen and the Rafoxifene analog LY117018: their effects on arachidonic acid release from cells in culture and on prostaglandin I2 production by rat liver cells.
Levine L
BMC Cancer; 2004 Aug; 4():49. PubMed ID: 15310397
[TBL] [Abstract][Full Text] [Related]
2. Lactacystin stimulates arachidonic acid metabolism in rat liver cells: effects of cell density on arachidonic acid release, PGI2 production and cyclooxygenase activity.
Levine L
Prostaglandins Leukot Essent Fatty Acids; 2000 Dec; 63(6):371-5. PubMed ID: 11133174
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen stimulates arachidonic acid release from rat liver cells by an estrogen receptor-independent, non-genomic mechanism.
Levine L
BMC Cancer; 2003 Sep; 3():24. PubMed ID: 14498998
[TBL] [Abstract][Full Text] [Related]
4. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
[TBL] [Abstract][Full Text] [Related]
5. Beta-adrenergic and arachidonic acid-mediated growth regulation of human breast cancer cell lines.
Cakir Y; Plummer HK; Tithof PK; Schuller HM
Int J Oncol; 2002 Jul; 21(1):153-7. PubMed ID: 12063562
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018.
Jordan VC; Gosden B
Endocrinology; 1983 Aug; 113(2):463-8. PubMed ID: 6872937
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of raloxifene and tamoxifen on the expression of estrogen receptors and antigen Ki-67 in human endometrial adenocarcinoma cell line.
Koda M; Jarzabek K; Haczynski J; Knapp P; Sulkowski S; Wolczynski S
Oncol Rep; 2004 Sep; 12(3):517-21. PubMed ID: 15289830
[TBL] [Abstract][Full Text] [Related]
8. In vitro bioeffects of the antiestrogen LY117018 on desmoid tumor and colon cancer cells.
Picariello L; Fiorelli G; Benvenuti S; Brandi ML; Galli G; Malentacchi C; Montali E; Bigozzi U; Ficari F; Tonelli F
Anticancer Res; 1997; 17(3C):2099-104. PubMed ID: 9216671
[TBL] [Abstract][Full Text] [Related]
9. Molecular effects of antiestrogens (tamoxifen and LY117018) on estrogen-dependent glycoprotein (USP-1) synthesized and secreted by rat uterine epithelial cells.
Takeda A; Shimizu S
Endocrinology; 1988 Jul; 123(1):258-63. PubMed ID: 3383775
[TBL] [Abstract][Full Text] [Related]
10. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.
Robertson JF
Cancer Treat Rev; 2004 Dec; 30(8):695-706. PubMed ID: 15541579
[TBL] [Abstract][Full Text] [Related]
11. Evidence for biological action of the antiestrogens LY117018 and tamoxifen by different mechanisms.
Black LJ; Goode RL
Endocrinology; 1981 Sep; 109(3):987-9. PubMed ID: 7262030
[TBL] [Abstract][Full Text] [Related]
12. The effect of tamoxifen on established human colorectal cancer cell lines in vitro.
Ziv Y; Gupta MK; Milsom JW; Vladisavljevic A; Kitago K; Fazio VW
Anticancer Res; 1996; 16(6B):3767-71. PubMed ID: 9042255
[TBL] [Abstract][Full Text] [Related]
13. Proteasome inhibitors: their effects on arachidonic acid release from cells in culture and arachidonic acid metabolism in rat liver cells.
Levine L
BMC Pharmacol; 2004 Aug; 4():15. PubMed ID: 15296516
[TBL] [Abstract][Full Text] [Related]
14. Lactoferricin-induced apoptosis in estrogen-nonresponsive MDA-MB-435 breast cancer cells is enhanced by C6 ceramide or tamoxifen.
Furlong SJ; Mader JS; Hoskin DW
Oncol Rep; 2006 May; 15(5):1385-90. PubMed ID: 16596215
[TBL] [Abstract][Full Text] [Related]
15. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer.
Jordan VC; O'Malley BW
J Clin Oncol; 2007 Dec; 25(36):5815-24. PubMed ID: 17893378
[TBL] [Abstract][Full Text] [Related]
16. Counteraction of estradiol-induced activation of tissue-type plasminogen activator in a human breast cancer cell line by an anti-estrogen, LY117018.
Uchiumi T; Mizoguchi H; Hagino Y; Kohno K; Kuwano M
Int J Cancer; 1991 Jan; 47(1):80-5. PubMed ID: 1702405
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release.
Kansra S; Yamagata S; Sneade L; Foster L; Ben-Jonathan N
Mol Cell Endocrinol; 2005 Jul; 239(1-2):27-36. PubMed ID: 15950373
[TBL] [Abstract][Full Text] [Related]
18. In vivo activation of gene transcription via oestrogen response elements by a raloxifene analogue.
Engdahl C; Jochems C; Gustafsson JA; van der Saag PT; Carlsten H; Lagerquist MK
J Endocrinol; 2009 Dec; 203(3):349-56. PubMed ID: 19752149
[TBL] [Abstract][Full Text] [Related]
19. Effects of tamoxifen on DNA adduct formation and arylamines N-acetyltransferase activity in human breast cancer cells.
Lee JH; Lu HF; Wang DY; Chen DR; Su CC; Chen YS; Yang JH; Chung JG
Res Commun Mol Pathol Pharmacol; 2004; 115-116():217-33. PubMed ID: 17564319
[TBL] [Abstract][Full Text] [Related]
20. Antiestrogenic effect of 20S-protopanaxadiol and its synergy with tamoxifen on breast cancer cells.
Yu Y; Zhou Q; Hang Y; Bu X; Jia W
Cancer; 2007 Jun; 109(11):2374-82. PubMed ID: 17464948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
